山东医药
山東醫藥
산동의약
SHANDONG MEDICAL JOURNAL
2014年
10期
25-27
,共3页
李广旭%宋平平%贾慧%李浩%张曙光%张百江
李廣旭%宋平平%賈慧%李浩%張曙光%張百江
리엄욱%송평평%가혜%리호%장서광%장백강
食管癌%新辅助放射治疗%新辅助化学治疗%细胞角化素蛋白片段19%癌胚抗原( CEA)%糖链抗原19-9
食管癌%新輔助放射治療%新輔助化學治療%細胞角化素蛋白片段19%癌胚抗原( CEA)%糖鏈抗原19-9
식관암%신보조방사치료%신보조화학치료%세포각화소단백편단19%암배항원( CEA)%당련항원19-9
esophageal carcinoma%neoadjuvant radiotherapy%neoadjuvant chemotherapy%cytokeratin 19 fragment (CYFRA21-1)%carcinoembryonic antigen%carbohydrate antigen 19-9
目的:探讨血清肿瘤标记物水平动态变化判断食管癌新辅助放化疗患者疗效及预后的价值。方法对30例行新辅助放化疗食管癌切除术患者的血清细胞角化素蛋白片段19( CYFRA21-1)、癌胚抗原( CEA )及糖链抗原19-9(CA19-9)水平行动态观察,分析其变化与临床疗效及预后的关系。结果治疗前CEA阳性者中位生存期明显短于CEA阴性者,P<0.05;CA19-9阳性者中位生存期短于CA19-9阴性者(但因阳性例数过少,无法行统计学处理);CYFRA21-1阳性与阴性者中位生存期无统计学差异。治疗过程中标志物呈下降趋势者中位生存期长于、有效率高于呈上升趋势者,P均<0.05。结论对食管癌新辅助放化疗患者血清CYFRA21-1、CEA及CA19-9联合动态及变化趋势检测,可评价治疗效果及判断预后。
目的:探討血清腫瘤標記物水平動態變化判斷食管癌新輔助放化療患者療效及預後的價值。方法對30例行新輔助放化療食管癌切除術患者的血清細胞角化素蛋白片段19( CYFRA21-1)、癌胚抗原( CEA )及糖鏈抗原19-9(CA19-9)水平行動態觀察,分析其變化與臨床療效及預後的關繫。結果治療前CEA暘性者中位生存期明顯短于CEA陰性者,P<0.05;CA19-9暘性者中位生存期短于CA19-9陰性者(但因暘性例數過少,無法行統計學處理);CYFRA21-1暘性與陰性者中位生存期無統計學差異。治療過程中標誌物呈下降趨勢者中位生存期長于、有效率高于呈上升趨勢者,P均<0.05。結論對食管癌新輔助放化療患者血清CYFRA21-1、CEA及CA19-9聯閤動態及變化趨勢檢測,可評價治療效果及判斷預後。
목적:탐토혈청종류표기물수평동태변화판단식관암신보조방화료환자료효급예후적개치。방법대30례행신보조방화료식관암절제술환자적혈청세포각화소단백편단19( CYFRA21-1)、암배항원( CEA )급당련항원19-9(CA19-9)수평행동태관찰,분석기변화여림상료효급예후적관계。결과치료전CEA양성자중위생존기명현단우CEA음성자,P<0.05;CA19-9양성자중위생존기단우CA19-9음성자(단인양성례수과소,무법행통계학처리);CYFRA21-1양성여음성자중위생존기무통계학차이。치료과정중표지물정하강추세자중위생존기장우、유효솔고우정상승추세자,P균<0.05。결론대식관암신보조방화료환자혈청CYFRA21-1、CEA급CA19-9연합동태급변화추세검측,가평개치료효과급판단예후。
Objective To discuss the dynamic changes of serum CYFRA 21-1, carcinoembryonic antigen (CEA) and carbohydrate antigen ( CA) 19-9 levels before and after neoadjuvant chemoradiotherapy to evaluate its efficacy and prognosis in treatment of patients with esophageal carcinoma .Methods The dynamic changes in serum levels of cytokeratin 19 frag-ment(CYFRA21-1), CEA and CA19-9 were observed during treatment and after treatment in 30 cases of patients who re-ceived neoadjuvant chemoradiotherapy with esophageal cancer resection .The relationship between the changes and the clin-ical efficacy and prognosis was analyzed .Results The median survival time of CEA positive people was significantly shor-ter than that of negative ones before treatment (P<0.05).The median survival time of CA19-9 positive people was shorter than that of negative ones ( because the positive cases were few , it was unable to statistical processing ) , and the median survival period of CYFRA21-1 positive and negative patients was not statistically different .During treatment, their median survival of those patients whose markers decreased was longer , and the effective rate was better than the increasing ones . Conclusions The dynamic and combined detections of serum CYFRA 21-1, CEA and CA19-9 in patients treated by preop-erative neoadjuvant chemotherapy can effectively evaluate the therapeutic effect and prognosis .